Table 3.
In vitro cytotoxicity of xanthone compounds 1–10 against WiDR and Vero cellsa
| Compound | IC50 (µg/mL)b
|
IC50 (µM)
|
SIc | ||
|---|---|---|---|---|---|
| WiDR | Vero | WiDR | Vero | ||
| 1 | 190.82±24.97 | 484.26±36.56 | 836.2±109.42 | 2,122.09±160.21 | 2.53 |
| 2 | 286.4±238.49 | 332.51±66.05 | 1,255.06±1,045.09 | 1,457.1±289.44 | 1.16 |
| 3 | 179.27±33.28 | 292.3±53.6 | 785.58±145.84 | 1,280.9±234.88 | 1.63 |
| 4 | 93.70±22.61 | 144.36±14.01 | 383.7±92.59 | 591.16±57.37 | 1.54 |
| 5 | 9.23±2.58 | 612.87±49.68 | 37.8±10.56 | 2,509.71±203.44 | 66.39 |
| 6 | 164.98±12.24 | 491.424±30.65 | 526.94±39.09 | 1,569.6±97.9 | 2.98 |
| 7 | 45.01±4.59 | >1,000 | 151.49±18.24 | >3,365.98 | >22.22 |
| 8 | 48.92±3.33 | 110.21±1.85 | 121.69±11.42 | 274.161 | 2.25 |
| 9 | 149.78±9.55 | >1,000 | 478.39±10.64 | >3,196.97 | >6.67 |
| 10 | 56.98±5.42 | 286.49±5.12 | 216.93±35.52 | 1,090.77±19.49 | 5.02 |
| Doxorubicin | 1.65±0.19 | 81.48±15.64 | 3.036±0.184 | 149.91±3.036 | 49.38 |
Notes:
a
Value is the mean of three experiments. The viable WiDR cells were calculated after 24 h of xanthone treatment and evaluated by using the MTT method.
b
CSIR criteria:36 inactive (mean IC50 >50 µg/mL), weak (15 µg/mL < mean IC50<50 µg/mL), moderate (6.25 µg/mL < mean IC50 <15 µg/mL), and potent (mean IC50 <6.25 µg/mL).
c
SI: selective if >3.
Abbreviations: CSIR, Council of Scientific and Industrial Research; IC50, inhibitory concentration 50%; SI, selectivity index.